Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Eli Lilly's orforglipron missed weight loss targets in a Phase 3 trial, but strong Q2 results and raised guidance highlight ...

New Delhi: Recommending to conduct post marketing surveillance (PMS) study in India, the Subject Expert Committee (SEC) ...

Weight-loss drugs spur debate and open new doors for CU Anschutz researcher studying food/brain relationshipOccasionally ...

This week, drugmakers had a scare when President Trump threatened to levy tariffs of up to 250% on imported pharmaceuticals.

August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.44. Operator: Good morning. My name is John, and I'll be your conference ...

In Oklahoma, approximately 405,800 adults have diabetes, and every year, about 26,000 adults in the state are diagnosed with the disease, according to the American Diabetes Association. In America, ...

Significant regulatory advances for lead candidate EB613 streamline Phase 3 clinical development and reduce regulatory hurdles. These 10 stocks could mint the next wave of millionaires › Entera Bio ...

In the 72-week phase 3 ATTAIN-1 trial, the once-daily oral GLP-1 receptor agonist orforglipron led to substantial weight loss ...

We remain confident in our global footprint and are well positioned to respond once more details are available. , said Biocon ...